Skip to main content
PYPD
NASDAQ Life Sciences

PolyPid Regains European Rights to D-PLEX100 After ADVANZ PHARMA Deal Ends

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$5.27
Mkt Cap
$107.043M
52W Low
$3.06
52W High
$5.73
52W Position info
72% above low
Off High info
8.0% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

PYPD sits 72% above its 52-week low of $3.06 on light trading volume (0.2× avg).

Summary

PolyPid and ADVANZ PHARMA mutually terminated their 2022 European license for D-PLEX100, returning exclusive commercialization rights to PolyPid. The European Medicines Agency has validated PolyPid’s Marketing Authorization Application for D-PLEX100. This follows the July Azurity deal for U.S./Canada rights and the FDA's Priority Review with a November 28 PDUFA date. Regaining Europe removes a legacy constraint and lets PolyPid seek a new partner for a major market, potentially on better terms given the positive Phase 3 data and regulatory progress. The company's cash position remains tight, so a new European deal could bring needed upfront payments. Watch for announcements of a new European partnership or licensing agreement.

At the time of this announcement, PYPD was trading at $5.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107M. The 52-week trading range was $3.06 to $5.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

PYPD - Latest Insights

PYPD
Nov 12, 2026, 8:39 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $6.97
Real-time Price: $6.16 info
Change: -$0.815 (-12%) info
Market Cap: $130.768M info
PYPD
Nov 11, 2026, 9:31 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $6.22
Real-time Price: $6.16 info
Change: -$0.0641 (-1%) info
Market Cap: $130.768M info
PYPD
Oct 28, 2026, 8:03 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.75
Real-time Price: $6.16 info
Change: +$0.405 (+7%) info
Market Cap: $130.768M info
PYPD
Oct 01, 2026, 9:20 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.30
Real-time Price: $6.16 info
Change: +$0.855 (+16%) info
Market Cap: $130.768M info
PYPD
Aug 12, 2026, 4:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.80
Real-time Price: $6.16 info
Change: +$1.36 (+28%) info
Market Cap: $130.768M info